PubMed Health⌕ Search

Biomedical subjects

D Dunlop

Publications and source records attributed to D Dunlop.

16 recordsLinked to original sources
PubMed1992

Extrapulmonary small cell carcinoma of bone.

Small cell carcinoma has been reported to arise in many extrathoracic sites. However, such tumours arising from bone have not been previously described. We report what we believe is the first reported case of extrapulmonary small cell carcinoma of bone. The tumour arose from the fifth dorsal vertebra in a 60 year old woman. The patient was treated with local radiotherapy and combination chemotherapy and remains in remission, 18 months after diagnosis. As such extrathoracic small cell tumours are rare, there seem to be no clear-cut guidelines for treating them, but combination chemotherapy is recommended.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1988

Botulinum toxin in ophthalmology.

Alan B. Scott selected, researched and developed Type A Botulinum toxin for clinical use in ophthalmology. This unique drug has proved invaluable for treatment of a number of conditions which are difficult to treat in ophthalmology and in a variety of other disciplines. The indications, methods and problems of its use are described and the results of treatment of 133 patients are discussed. Up to December 1986 over 13,000 patients have been treated in a multicentre international trial without significant complications.

Aged↗
PubMed1986

Propranolol pharmacokinetics during the menstrual cycle.

The pharmacokinetics of propranolol during menstruation and in the mid menstrual cycle have been studied in nine young women taking a single 80 mg tablet on each occasion. There were wide between-individual differences in the serum concentration at any given time (4-5 fold at peak concentrations) but the serum concentration time curves within individuals showed only mild variations. The differences between the average pharmacokinetic parameter estimates for the group did not differ significantly between the two periods of study.

Adolescent↗
PubMed1986

Global stereopsis in stroke patients.

Contradictory evidence has been presented in the literature on the existence of a right-hemisphere mechanism subserving global stereopsis. In the present study evoked responses to dynamic random-dot stereograms were recorded from International 10-20 scalp sites O2, P4, T6, T4 and homotopic sites over the left hemisphere. Stroke patients with unilateral lesions were selected on the basis of satisfactory performance on ocular screening tests and on clinical or objective indications that dementia was absent. Control subjects were found among the relatives of patients. The stereopsis test schedule included left, right and centre field presentations of 30 arc min, disparities. The dot density of the disparity, relative to that of the remainder of the random dot field, was manipulated to provide a full contrast stimulus and a no-contrast uniform field stimulus, thus varying the availability of monocular cues provided by the contrast factor. Latency and amplitude of the evoked potentials were computed and submitted to analyses of variance. No significant results were found which supported the proposition of a lateralized mechanism for global stereopsis. This conclusion is in conflict with the findings of some earlier reports. It is suggested that the techniques used in the earlier experiments may not have been adequate for the study of the questions involved.

Aged↗
PubMed1979

Compartments of protein metabolism in the developing brain.

We investigated whether the higher rate of amino acid incorporation into immature than into mature brain protein is due to (a) rapid growth, (b) a small rapidly metabolized protein pool, or (c) a higher turnover rate of most of the protein. We measured net growth and the incorporation of [14C]tyrosine or [14C]valine into brain proteins in young rats and mice. The specific activity of the free amino acid pool was kept constant in the tyrosine experiments. Incorporation of tyrosine into protein was continued for up to 30 h by which time the specific activity of protein-bound amino acid reached 1/3 of that of the free (precursor) amino acid. The growth (accretion) of brain proteins was approx. 0.635% per h in mice and rats in the 1-4 day period after birth. In previous studies we found that the turnover rate of the bulk (about 96%) of adult brain proteins is below 0.3% per h. Because of the presence of a small (about 4%) active pool the average turnover rate is 0.6% per h. The present experiments show a degradation rate of 0.7-1.1% per h in the brain proteins of the young. This high metabolic rate is not due to a small rapidly degraded fraction of protein. The very rapid protein fraction previously seen in adult rats is either very small (below 1%) or absent in the young. Thus most of the proteins in the immature brain during the rapid growth phase are formed and broken down at a rate that is approximately three times higher than that of the bulk of proteins in the adult brain. The small active protein pool in the adult on the other hand has a metabolic rate higher than that of the immature brain proteins.

Aging↗
PubMed1979

Infant strabismus: a 25-year review of 750 cases.

The review demonstrates that there is no justification for delay in treating babies who present with strabismus. A survey of 750 infants aged from 0 to 36 months among 5497 cases seen by an individual orthoptist over 25 years shows a decreasing use of surgery and an increasing proportion of fully functional results over this time. It emphasizes that no infant is too young for assessment and treatment.

Age Factors↗
PubMed1977

Ruth Pybus.

Explore the source record for details and available documents.

Diabetes Mellitus↗
PubMedDate not supplied

An alternating chemotherapy combination (MACOBLE) for intermediate and high-grade non-Hodgkin's lymphoma.

From June 1983 to February 1986, 48 patients with intermediate or high-grade non-Hodgkin's lymphomas (NHL) received a CHOP based combination with the addition of etoposide on days 1 and 2, bleomycin days 1 and 10 and methotrexate 1.5 g/m2 on day 10 (MACOBLE). Their median age was 59 years, 20 (42 per cent) had an ECOG performance status (PS) of 2 or 3, 24 (50 per cent) had stage IV disease, 25 (52 per cent) B symptoms and 21 (44 per cent) bulk (greater than 10 cm) disease. With a median follow-up of 62 months, 12 patients are alive, 10 of whom are disease-free. Median overall survival was 13 months (95 per cent confidence interval 6-23 months) with actuarial 5-year survival of 25 per cent (95 per cent confidence interval 13-37 per cent). Factors associated with inferior survival were ECOG PS 2 or 3 (P = 0.004), B symptoms (P = 0.013) and bulk disease (P = 0.017). These data suggest that, when treating an unselected patient population, attempts to increase the intensity of first-line chemotherapy may not improve the outcome.

Adult↗